Blood Res 2023; 58(S1):
Published online April 30, 2023
https://doi.org/10.5045/br.2023.2023037
© The Korean Society of Hematology
Correspondence to : Jae-Cheol Jo, M.D., Ph.D.
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 25 Daehakbyeongwon-ro, Dong-gu, Ulsan 44033, Korea
E-mail: jcjo@uuh.ulsan.kr; jcjo@ulsan.ac.kr
#These authors contributed equally to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
T-cell large granular lymphocyte (T-LGL) leukemia is characterized by clonal expansion of cytotoxic T cells resulting in cytopenia. The proliferation of clonal LGLs is caused by prolonged antigenic stimulation, which leads to apoptotic dysregulation owing mainly to the constitutive activation of survival pathways, notably the JAK/STAT pathway. Understanding how leukemic T-LGL persists can aid in the development of future immunosuppressive therapies. In this review, we summarize the diagnosis and current standard of therapy for T-LGL leukemia, as well as recent advances in clinical trials.
Keywords T-cell large granular lymphocyte leukemia, Diagnosis, Treatment
Blood Res 2023; 58(S1): S52-S57
Published online April 30, 2023 https://doi.org/10.5045/br.2023.2023037
Copyright © The Korean Society of Hematology.
Sang Hyuk Park1#, Yoo Jin Lee2#, Youjin Kim2, Hyun-Ki Kim1, Ji-Hun Lim1, Jae-Cheol Jo2
1Department of Laboratory Medicine, 2Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Correspondence to:Jae-Cheol Jo, M.D., Ph.D.
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 25 Daehakbyeongwon-ro, Dong-gu, Ulsan 44033, Korea
E-mail: jcjo@uuh.ulsan.kr; jcjo@ulsan.ac.kr
#These authors contributed equally to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
T-cell large granular lymphocyte (T-LGL) leukemia is characterized by clonal expansion of cytotoxic T cells resulting in cytopenia. The proliferation of clonal LGLs is caused by prolonged antigenic stimulation, which leads to apoptotic dysregulation owing mainly to the constitutive activation of survival pathways, notably the JAK/STAT pathway. Understanding how leukemic T-LGL persists can aid in the development of future immunosuppressive therapies. In this review, we summarize the diagnosis and current standard of therapy for T-LGL leukemia, as well as recent advances in clinical trials.
Keywords: T-cell large granular lymphocyte leukemia, Diagnosis, Treatment
Hyun Jung Lee
Blood Res 2023; 58(S1): S96-S108Hyewon Lee
Blood Res 2023; 58(S1): S66-S82Hyojin Ahn, Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee
Blood Res 2022; 57(S1): S101-S111